Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 10/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196377 | 1.00 | GCK (0.41) | GCKHSD17B1HSD17B2KDM4EKMT2A | |
| SCHEMBL3358060 | 0.87 | GCK (0.40) | GCKHSD17B1HSD17B2KMT2AMAPT | |
| SCHEMBL2384771 | 0.84 | GCK (0.41) | GCKHSD17B1HSD17B2KMT2A | |
| SCHEMBL2384776 | 0.84 | GCK (0.41) | GCKHSD17B1HSD17B2KMT2A | |
| SCHEMBL12252617 | 0.79 | GCK (0.42) | GCKHSD17B1HSD17B2KDM4E | |
| SCHEMBL2196324 | 0.78 | GCK (0.41) | GCKHSD17B1HSD17B2KDM4EKMT2A | |
| SCHEMBL2196327 | 0.78 | GCK (0.41) | GCKHSD17B1HSD17B2KDM4EKMT2A | |
| SCHEMBL1711660 | 0.78 | GCK (0.41) | GCKHSD17B1HSD17B2 | |
| SCHEMBL1711662 | 0.78 | GCK (0.41) | GCKHSD17B1HSD17B2 | |
| SCHEMBL1711634 | 0.78 | GCK (0.46) | GCKKDM4ECTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HSD17B1 696/4885HSD17B2 839/4885 |
| US-20110230445-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HSD17B1 716/4885HSD17B2 864/4885 |
| US-20100063063-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HSD17B1 716/4885HSD17B2 864/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | GCK 2/4885HSD17B1 716/4885HSD17B2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.